IgA Nephropathy Biomarkers Evaluation Study (INTEREST)

Launched by SUN YAT-SEN UNIVERSITY · Nov 2, 2016

Keywords

ClinConnect Summary

The INTEREST study is looking into how certain markers in blood and urine can help predict the long-term progression of IgA nephropathy, a kidney disease. This research will involve about 2,000 people in China who have been diagnosed with this condition but still have relatively normal kidney function. By examining these biomarkers, researchers hope to better understand how the disease develops and how to manage it effectively over time.

To participate, you need to be at least 14 years old and have a confirmed diagnosis of primary IgA nephropathy, confirmed through a kidney biopsy. This biopsy should have been done within the last three years and must show a sufficient number of kidney structures for review. Participants will be asked to give their consent and will be closely monitored as part of the study. It’s important to note that individuals with a family history of IgA nephropathy or those with other health conditions causing similar symptoms will not be eligible. This study is currently recruiting participants, so if you think you might qualify, it could be a great opportunity to contribute to important research in kidney health.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Male or female individuals aged 14 years or older
• • Patients with biopsy-proven primary IgA nephropathy
• • A renal biopsy available for reviewing must include 10 or more glomeruli.
• • The first renal biopsy was performed within 3 years.
• • eGFR ≥ 60 ml/min/1.73 m2 (MDRD formula);
• • Individuals or their legal representative who are able to understand and have voluntarily signed the informed consent form (ICF).
• Exclusion Criteria:
• • Relatives were diagnosed with biopsy-proven primary IgA nephropathy;
• • Individuals had secondary IgA nephropathy due to diseases such as diabetes, chronic liver disease and systemic lupus erythematosus.